A new study reveals that certain medications commonly prescribed for irritable bowel syndrome carry a small but measurable association with increased mortality risk, raising questions about long-term treatment strategies for this widespread digestive disorder.
Researchers examining large health databases found that patients taking anticholinergic drugs, a class of medications used to manage IBS symptoms like cramping and urgency, showed slightly elevated rates of early death compared to those not taking these medications. The association remained even after accounting for other health factors.
Anticholinergic medications work by blocking signals in the nervous system that trigger gut contractions. They're prescribed frequently for IBS because they reduce abdominal pain and bathroom urgency. Common drugs in this category include dicyclomine and hyoscyamine.
The study doesn't prove these medications cause death. Instead, it identifies a correlation that warrants closer investigation. Researchers suspect the link may stem from how anticholinergics affect the broader body. These drugs can increase heart rate, raise blood pressure, and potentially impact cognitive function in older adults. Long-term use might compound these effects over years of treatment.
The absolute risk remains small. For most people taking these medications short-term or in appropriate doses, the benefits of symptom relief may outweigh theoretical risks. However, the findings highlight the need for individualized treatment plans and regular monitoring, particularly for older patients or those taking multiple medications.
Gastroenterologists now emphasize exploring alternative first-line treatments for IBS, including dietary modifications like the low-FODMAP diet, cognitive behavioral therapy, and newer medications like linaclotide or lubiprostone that work differently than anticholinergics. These approaches show effectiveness without the potential mortality signals.
Patients currently taking anticholinergic medications should not stop abruptly. Instead, this research supports conversations with doctors about whether continuing these drugs remains necessary, whether lower